Cite
HARVARD Citation
Zabana Abdo, Y. et al. (n.d.). DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. Journal of Crohn's and colitis. pp. S078-S079. [Online].